Jupiter Topco LLC bought a new position in shares of Kenvue Inc. (NYSE:KVUE – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 397,673 shares of the company’s stock, valued at approximately $7,600,000.
Other large investors have also bought and sold shares of the company. Kintayl Capital LP bought a new stake in shares of Kenvue in the 2nd quarter valued at about $7,094,000. Hsbc Holdings PLC raised its position in shares of Kenvue by 34.3% during the second quarter. Hsbc Holdings PLC now owns 7,544,394 shares of the company’s stock worth $143,893,000 after acquiring an additional 1,926,217 shares during the last quarter. Ancora Advisors LLC bought a new position in shares of Kenvue during the second quarter worth about $313,000. Canada Pension Plan Investment Board acquired a new position in shares of Kenvue in the second quarter worth approximately $74,895,000. Finally, Kapitalo Investimentos Ltda acquired a new position in shares of Kenvue in the second quarter worth approximately $1,108,000. 97.64% of the stock is owned by institutional investors.
Kenvue Price Performance
Shares of KVUE opened at $19.15 on Monday. The firm has a market cap of $36.78 billion, a PE ratio of 22.01, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $20.82. The business’s 50 day moving average price is $19.16 and its two-hundred day moving average price is $18.25. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01.
Kenvue Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th were issued a $0.21 dividend. The ex-dividend date was Wednesday, August 12th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. Kenvue’s dividend payout ratio is 96.55%.
Analysts Set New Price Targets
KVUE has been the subject of a number of recent analyst reports. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Barclays boosted their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Finally, UBS Group lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $19.27.
Check Out Our Latest Stock Report on Kenvue
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
See Also
- Five stocks we like better than Kenvue
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
